Assessment of human effective absorbed dose of 67 Ga-ECC based on biodistribution rat data.

Objective: In a diagnostic context, determination of absorbed dose is required before the introduction of a new radiopharmaceutical to the market to obtain marketing authorization from the relevant agencies. In this work, the absorbed dose of [67 Ga]-ethylenecysteamine cysteine [(67 Ga)ECC] to human organs was determined by using distribution data for rats.

Methods: For biodistribution data, the animals were sacrificed by CO2 asphyxiation at selected times after injection (0.

Development of (111)In-labeled porphyrins for SPECT imaging.

Objectives: The aim of this research was the development of (111)In-labeled porphyrins as possible radiopharmaceuticals for the imaging of tumors.

Methods: Ligands, 5, 10, 15, 20-tetrakis (3, 5-dihydroxyphenyl) porphyrin) (TDHPP), 5, 10, 15, 20-tetrakis (4-hydroxyphenyl) porphyrin (THPP) and 5, 10, 15, 20-tetrakis (3,4-dimethoxyphenyl) porphyrin) (TDMPP) were labeled with (111)InCl3 (produced from proton bombardment of natCd target) in 60 min at 80 ºC. Quality control of labeled compounds was performed via RTLC and HPLC followed by stability studies in final formulation and presence of human serum at 37 ºC for 48 h as well as partition coefficient determination.

Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats.

In this work, the absorbed dose to each organ of human for (166)Ho-TTHMP was evaluated based on biodistribution studies in rats by a RADAR method and was compared with (166)Ho-DOTMP as the only clinically used Ho-166 bone marrow ablative agent. The highest absorbed dose for this complex is observed in red marrow with 0.922mGy/MBq.

Assessment of the effective absorbed dose of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine in humans on the basis of biodistribution data of rats.

Objectives: The aim of this study was to estimate the effective absorbed radiation dose to human organs following promising in-vivo results of intravenous administration of 4-benzyl-1-(3-[125I]-iodobenzylsulfonyl)piperidine (4-B-[125I]-IBSP) using normal biodistribution data obtained from rats.

Materials And Methods: Five rats were killed at exact time intervals and the percentage of injected dose per gram of each organ was measured by direct counting from rat data. The medical internal radiation dose formulation was applied to extrapolate from rats to humans and to project the absorbed radiation dose for various human organs.

Establishment of a fast and high yield method for routine production of [(131) I]MIBG and investigation of its radiochemical stability for diagnosis and treatment uses.

In this work, exchange radioiodination of metaiodobenzylguanidine (MIBG) was carried out at optimum conditions that facilitates the production of [(131) I]MIBG both quickly and efficiently. The radiochemical purity and yield of the labeled product are typically as high as 99% and 90% for diagnostic dose and 95% and 80% for therapeutic dose, respectively. Stability studies show that labeled material at the room temperature met the demand of the clinical application.

Design and construction of a thermal neutron beam for BNCT at Tehran Research Reactor.

An irradiation facility has been designed and constructed at Tehran Research Reactor (TRR) for the treatment of shallow tumors using Boron Neutron Capture Therapy (BNCT). TRR has a thermal column which is about 3m in length with a wide square cross section of 1.2×1.

Effective delayed neutron fraction and prompt neutron lifetime of Tehran research reactor mixed-core.

In this work, kinetic parameters of Tehran research reactor (TRR) mixed cores have been calculated. The mixed core configurations are made by replacement of the low enriched uranium control fuel elements with highly enriched uranium control fuel elements in the reference core. The MTR_PC package, a nuclear reactor analysis tool, is used to perform the analysis.

A feasibility study of the Tehran research reactor as a neutron source for BNCT.

Investigation on the use of the Tehran Research Reactor (TRR) as a neutron source for Boron Neutron Capture Therapy (BNCT) has been performed by calculating and measuring energy spectrum and the spatial distribution of neutrons in all external irradiation facilities, including six beam tubes, thermal column, and the medical room. Activation methods with multiple foils and a copper wire have been used for the mentioned measurements. The results show that (1) the small diameter and long length beam tubes cannot provide sufficient neutron flux for BNCT; (2) in order to use the medical room, the TRR core should be placed in the open pool position, in this situation the distance between the core and patient position is about 400 cm, so neutron flux cannot be sufficient for BNCT; and (3) the best facility which can be adapted for BNCT application is the thermal column, if all graphite blocks can be removed.

Synthesis and evaluation of a 99mTc-labeled tubulin-binding agent for tumor imaging.

Cholchicine and its derivatives are very potent tubulin-binding compounds and can be used as a potential tumor targeting agents. In this study, colchicine was labeled with (99m) Tc via hydrazinonicotinic acid (HYNIC) and was investigated further. HYNIC/cholchicine was synthesized and labeling with (99m)Tc was performed at 95 °C for 15 min and radiochemical analysis included HPLC method.

Calculation of water equivalent ratio of several dosimetric materials in proton therapy using FLUKA code and SRIM program.

Water equivalent ratio (WER) was calculated for different proton energies in polymethyl methacrylate (PMMA), polystyrene (PS) and aluminum (Al) using FLUKA and SRIM codes. The results were compared with analytical, experimental and simulated SEICS code data obtained from the literature. The biggest difference between the codes was 3.

Preparation of 99mTc-TRODAT-1 with high labeling yield in boiling water bath: a new formulation.

A new formulation for preparation of (99m)Tc-labeled tropane derivative, (99m)Tc-TRODAT-1, which is useful as a potential CNS dopamine transporter imaging agent, was evaluated and characterized. Preparation of (99m)Tc-TRODAT-1 was attained previously by a formulation in which vial has to be autoclaved at 121 °C for 30 min. It is highly desirable to further improve the preparation method by developing a simplified one vial formulation which will be labeled in boiling water bath (95 °C) for 15 min and a high labeling yield will be achieved.

Radiosynthesis and Quality Control of [(67)Ga]-3,4-dimethoxylated Porphyrin Complex as a Possible Imaging agent.

Radiolabeled porphyrins are potential tumor avid radiopharmaceuticals because of their impersonation in the human body, ability to complex various radionuclides, water solubility, low toxicity etc. In this work a radiogallium porphyrin complex has been developed. [(67)Ga] labeled 5,10,15,20-tetrakis(3,4-dimethoxyphenyl) porphyrin ([(67)Ga]-TDMPP) was prepared using freshly prepared [(67)Ga]GaCl3 and 5,10,15,20-tetrakis(3,4-dimethoxyphenyl) porphyrin (H2TDMPP) for 60 min at 100°C.

A small size 1-3 atm pulsed CO2 laser with series-connected spark gaps ultraviolet preionization.

A small size pulsed CO2 laser with rounded edge flat profiled electrodes and variable gas pressure in 1-3 atm range has been constructed and characterized. The perionization system consists of a pair of 16 series-connected spark gaps located along either side of the main electrodes by which, the number of required preionization capacitors is reduced to 4. Sharpening of the main discharge has been performed using a 300 pF peaking capacitor.

A (99m) Tc-tricine-HYNIC-labeled peptide targeting the neurotensin receptor for single-photon imaging in malignant tumors.

In this study, a new neurotensin (NT) analog was labeled with (99m) Tc via HYNIC chelator and tricine as coligand and investigated further. An NT (7-13) analog was prepared, and labeling with (99m) Tc was performed. The internalization rate and biodistribution of radiopeptide were studied in HT-29 cells and nude mice bearing tumor, respectively.

(99m) Tc-tricabonyl labeling of ofloxacin and its biological evaluation in Staphylococcus aureus as an infection imaging agent.

Even in recent decades, one of the major causes of death and unhealthiness in the whole world is infection and inflammation. The use of radiopharmaceuticals is a powerful tool in managing the patients with infectious diseases. In this study, ofloxacin as a second-generation fluoroquinolone has been labeled with [(99m) Tc(CO)3 (H2 O)3 ](+) core to formulate a suitable infection imaging agent.

Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.

Objectives: In this study, production, quality control, and biodistribution studies of a newly developed therapeutic compound have been presented and are followed by dosimetric evaluation for use in humans based on biodistribution data in wild-type rats.

Materials And Methods: The Lu-1,2-propylene di-amino tetramethylenephosphonic acid (Lu-PDTMP) complex was prepared successfully using synthesized PDTMP ligand and LuCl3. LuCl3 was obtained by thermal neutron irradiation (4×10 n/cm/s) of enriched Lu2O3 samples.

Optimization of the beam shaping assembly in the D-D neutron generators-based BNCT using the response matrix method.

Optimization of the Beam Shaping Assembly (BSA) has been performed using the MCNP4C Monte Carlo code to shape the 2.45 MeV neutrons that are produced in the D-D neutron generator. Optimal design of the BSA has been chosen by considering in-air figures of merit (FOM) which consists of 70 cm Fluental as a moderator, 30 cm Pb as a reflector, 2mm (6)Li as a thermal neutron filter and 2mm Pb as a gamma filter.

Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.

Objective(s): In this study, (166)Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) ((166)Ho-PDTMP) complex was prepared as a bone palliation agent.

Materials And Methods: The complex was successfully prepared using an in-house synthesized EDTMP ligand and (166)HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.

Development of (177)Lu-phytate Complex for Radiosynovectomy.

Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation.

Materials And Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 10(13) n.

Thermoluminescent and Monte Carlo dosimetry of a new 170Tm brachytherapy source.

In this Study characteristics of a new 170Tm brachytherapy seed using thermoluminescent dosimeter and also the Monte Carlo simulations to evaluate between calculated and measured values was determined. Titanium tube contained Tm(NO3)3 powders bombardment at the Tehran Research Reactor (TRR) for a period of 7 days at a flux of 2-3 × 10(13) neutrons/cm2 s. To obtain the radial dose function, g(r), and the anisotropy function, F(r, θ), according to the AAPM TG-43U1 recommendations, 30 cm × 30 cm × 15 cm phantoms of Perspex slabs were used.

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis.

Introduction: Involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. Due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. Although these kinds of therapies have many advantages including the ability to treat multiple sites of tumoral involvement simultaneously, no significant confliction with other treatments, ease of administration and the potential to be used repetitively; in Iran using of this modality is not widely practiced.

Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.

Somatostatin-derived analogues play an important role in the diagnosis and treatment of neuroendocrine tumors. The aim of this study was to evaluate a new somatostatin analogue designed for labeling with (99m)Tc: [6-hydrazinopyridine-3-carboxylic acid (HYNIC(0)), β-(3-benzothienyl)-Ala (BzThi(3))]-octreotide ([HYNIC]-BOC), using ethylenediamine-N,N'-diacetic acid (EDDA) and tricine as coligands. Synthesis was performed on a solid phase using a standard Fmoc strategy.

A modified homotopy perturbation method and the axial secular frequencies of a non-linear ion trap.

In this paper, a modified version of the homotopy perturbation method, which has been applied to non-linear oscillations by V. Marinca, is used for calculation of axial secular frequencies of a non-linear ion trap with hexapole and octopole superpositions. The axial equation of ion motion in a rapidly oscillating field of an ion trap can be transformed to a Duffing-like equation.

Development of a (68)Ga-Fluorinated Porphyrin Complex as a Possible PET Imaging Agent.

Aim: Due to the interesting pharmacologic properties of porphyrins, the idea of developing a possible tumor imaging agent using PET by incorporating (68)Ga into a suitable porphyrin ligand was investigated.

Methods: (68)Ga-labeled 5,10,15,20-tetrakis(pentafluoro-13 phenyl) porphyrin ((68)Ga-TFPP) was prepared using freshly eluted [(68)Ga]GaCl3 obtained from a 68Ge/68Ga generator developed in-house and 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (H2TFPP) for 60 min at 100°C.

Results: The complex was prepared with high radiochemical purity (>99% ITLC, >99% HPLC, specific activity: 13-14 GBq/mmol).

Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials.

Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid ((177)Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, (177)Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and (177)LuCl3.